Clinical-stage biotechnology company
Appears in 1 story · Last updated Sep 9, 2026
As of September 2026: Developing afimetoran and four other immunology programs
Beeline Medicines' afimetoran, a once-daily oral pill for lupus, met its primary endpoint in a Phase 2 trial. The result moves the biotech into Phase 3 (pivotal) development for two forms of the disease.
Updated Sep 9
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
